News

Bioeq is also the exclusive holder of the global commercialisation rights for the medicine, Formycon’s biosimilar candidate for Lucentis (ranibizumab). This agreement allows Bio Usawa to register and

The move is said to bolster the company’s North America and Europe presence, meeting the worldwide demand for critical injectable therapeutics. This expansion has enlarged the total production

This agreement grants Qilu exclusive rights to develop, manufacture, enhance, utilise and commercialise Albipagrastim alfa for Injection in Greater China including Chinese Mainland, Macau, Hong Kong and Taiwan.

Mazdutide is a dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist. The therapy’s unique dual mechanism not only promotes weight loss but also targets visceral fat and enhances metabolic

Paediatric HGG, including ependymoma, are not only rare but also very difficult to treat, with current standard care failing to prevent recurrence and with five-year survival rates. Reyobiq

This follows a similar endorsement by the US Food and Drug Administration (FDA). Sanfilippo syndrome type B is an autosomal recessive disease marked by mutations in the N-acetyl-alpha-glucosaminidase

This collaboration appoints Optime Care as the exclusive specialty pharmacy provider for the newly FDA-approved tablets, ensuring the medication’s availability to patients.  Optime Care general manager Bill Bertetto

This new small molecule is designed for prostate cancer imaging and treatment.   The FDA’s approval allows Archeus to begin a Phase I clinical study targeting metastatic castration-resistant prostate

The therapy is intended to treat the adult population with haematological malignancies needing an allogeneic haematopoietic stem cell transplantation after a myeloablative conditioning for those individuals with no